Valo Therapeutics

Private

HelsinkiHealthcare & Life Scienceshttps://valotx.com

Last Round

Early Funding

Mar 10, 2025

Total Funding Raised

$40.29M

Company Overview

Valo Therapeutics is a biotechnology company that develops novel immunotherapies for cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

cancer immunotherapyimmuno-oncologyoncolytic virus therapyoncolytic virotherapytherapeutic vaccinescancer vaccinesPeptiCRAdpeptide vaccinespeptide coatingadenovirus vectorsolid tumor treatmentpersonalized immunotherapyneoantigen vaccineneoantigen identificationantigen discoveryPeptiCHIPclinical-stage biotechpharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Valo Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Valo Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Mar 10, 2025
Grant	Feb 14, 2023
Series A	Nov 15, 2021
Debt	Jul 4, 2017

View all Funding Rounds

Key People

Founding team and executive leadership

Marcella Origgi

CEO Of ValoTX OY And Of Valo SRL

Executive Team

Sari Pesonen

Chief Scientific Officer, Chief Executive Officer

Executive Team

Harri Järveläinen

Chief Operating Officer

Executive Team

Valo Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Freeman Road	Early Funding
European Innovation Council	Grant
Indaco Venture Partners SGR	Early Funding
CDP Venture Capital SGR	Early Funding
Tekes	Debt
ENEA-Tech and Biomedical Foundation	Early Funding

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 9, 2025
Marcella Origgi joins as the new CEO, coming from Johnson & Johnson Innovation.
Mar 10, 2025
$21M raised in early funding.

View all signals

Valo Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Valo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Valo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHelsinki

Employee Range10

Year Founded2016

Last FundingMar 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.